Nasdaq · CIK 0001478320
ADPT Adaptive Biotechnologies Corp
Insider trading from SEC Form 4. Last filing 4 d ago. Close $26.49 on Oct 9, 2026, +113% from the 52-week low and -11% from the high.
Last 90 days
Net insider value
-$6.2M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
6
$6.2M by 3 insiders
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
ADPTOct 9, 2026 · close 26.49
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Adaptive Biotechnologies Corp, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 24Weak | Julie Rubinstein President and COO sell | $948k 35,643 shares | -9% | +117% from low-10% from high | |
| 22Weak | Susan Bobulsky Chief Commercial Officer, MRD sell | $193k 6,444 shares | -2% | +117% from low-10% from high | |
| 22Weak | Francis Lo Chief People Officer sell | $758k 26,792 shares | -11% | +121% from low-7% from high | |
| 25Weak | Julie Rubinstein President and COO sell | $1.0M 35,643 shares | -9% | +121% from low-7% from high | |
| 23Weak | Francis Lo Chief People Officer sell | $3.2M 115,406 shares | -34% | +123% from low0% from high | |
| 8Weak | Susan Bobulsky Chief Commercial Officer, MRD sell | $32k 1,195 shares | -0% | +115% from low0% from high | |
| 22Weak | Kyle Piskel Chief Financial Officer sell | $17k 1,929 shares | -1% | +126% from low-10% from high | |
| 0Weak | Harlan S Robins Chief Scientific Officer sell | $503k 68,412 shares | -5% | +84% from low-15% from high | |
| 0Weak | Harlan S Robins Chief Scientific Officer sell | $15k 1,698 shares | -0% | +117% from low0% from high | |
| 63Notable | Michelle Renee Griffin director sell | $261k 36,291 shares | -70% | +79% from low-16% from high | |
| 23Weak | Peter M Neupert director sell | $71k 10,000 shares | -4% | +67% from low-22% from high | |
| 56Moderate | Robert Hershberg director sell | $402k 53,000 shares | -43% | +91% from low-11% from high | |
| 25Weak | Michelle Renee Griffin director sell | $124k 15,664 shares | -23% | +94% from low-9% from high | |
| 65Notable | Chad M Robins CEO and Chairman sell | $1.6M 219,569 shares | -7% | +101% from low-6% from high | |
| 50Moderate | Harlan S Robins Chief Scientific Officer sell | $675k 96,656 shares | -7% | +101% from low-6% from high | |
| 51Moderate | Julie Rubinstein President and COO sell | $416k 59,505 shares | -9% | +101% from low-6% from high | |
| 45Moderate | Kyle Piskel Chief Financial Officer sell | $72k 10,320 shares | -4% | +101% from low-6% from high | |
| 49Moderate | Sharon Benzeno Chief Commercial Ofc Imm Med sell | $312k 44,665 shares | -10% | +101% from low-6% from high | |
| 42Moderate | Susan Bobulsky Chief Commercial Officer, MRD sell | $182k 26,023 shares | -7% | +101% from low-6% from high | |
| 41Moderate | Francis Lo Chief People Officer sell | $146k 20,875 shares | -6% | +101% from low-6% from high | |
| 35Weak | Chad M Robins CEO and Chairman sell | $2.4M 285,187 shares | -10% | +109% from low-2% from high | |
| 20Weak | Chad M Robins CEO and Chairman sell | $4.0M 470,368 shares | -18% | +113% from low0% from high | |
| 22Weak | Kyle Piskel Chief Financial Officer sell | $1,235 248 shares | -0% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Susan Bobulsky Chief Commercial Officer, MRD | SOpen-market sale Common Stock10b5-1 | -6,444 | $30.00 | $193k | 389,350 | 4 d ago |
| Oct 6, 2026 | Julie Rubinstein President and COO | MOption exercise Common Stock10b5-1 | +11,881 | $12.14 | $144k | 389,683 | 4 d ago |
| Oct 6, 2026 | Julie Rubinstein President and COO | SOpen-market sale Common Stock10b5-1 | -9,381 | $27.36 | $257k | 380,302 | 4 d ago |
| Oct 6, 2026 | Julie Rubinstein President and COO | SOpen-market sale Common Stock10b5-1 | -1,100 | $28.21 | $31k | 379,202 | 4 d ago |
| Oct 6, 2026 | Julie Rubinstein President and COO | SOpen-market sale Common Stock10b5-1 | -901 | $29.71 | $27k | 378,301 | 4 d ago |
| Oct 6, 2026 | Julie Rubinstein President and COO | SOpen-market sale Common Stock10b5-1 | -499 | $30.53 | $15k | 377,802 | 4 d ago |
| Oct 7, 2026 | Julie Rubinstein President and COO | MOption exercise Common Stock10b5-1 | +11,881 | $12.14 | $144k | 389,683 | 4 d ago |
| Oct 7, 2026 | Julie Rubinstein President and COO | SOpen-market sale Common Stock10b5-1 | -11,881 | $26.40 | $314k | 377,802 | 4 d ago |
| Oct 8, 2026 | Julie Rubinstein President and COO | MOption exercise Common Stock10b5-1 | +11,881 | $12.14 | $144k | 389,683 | 4 d ago |
| Oct 8, 2026 | Julie Rubinstein President and COO | SOpen-market sale Common Stock10b5-1 | -11,881 | $25.66 | $305k | 377,802 | 4 d ago |
| Oct 6, 2026 | Julie Rubinstein President and COO | MOption exercise Stock Option (right to buy)derivative10b5-1 | -11,881 | $0.00 | $0 | 332,253 | 4 d ago |
| Oct 7, 2026 | Julie Rubinstein President and COO | MOption exercise Stock Option (right to buy)derivative10b5-1 | -11,881 | $0.00 | $0 | 320,372 | 4 d ago |
| Oct 8, 2026 | Julie Rubinstein President and COO | MOption exercise Stock Option (right to buy)derivative10b5-1 | -11,881 | $0.00 | $0 | 308,491 | 4 d ago |
| Oct 1, 2026 | Francis Lo Chief People Officer | MOption exercise Common Stock10b5-1 | +8,038 | $8.46 | $68k | 228,905 | 7 d ago |
| Oct 1, 2026 | Julie Rubinstein President and COO | MOption exercise Common Stock10b5-1 | +11,881 | $12.14 | $144k | 389,683 | 7 d ago |
| Oct 1, 2026 | Francis Lo Chief People Officer | MOption exercise Common Stock10b5-1 | +9,377 | $3.99 | $37k | 238,282 | 7 d ago |
| Oct 1, 2026 | Julie Rubinstein President and COO | SOpen-market sale Common Stock10b5-1 | -6,081 | $27.57 | $168k | 383,602 | 7 d ago |
| Oct 1, 2026 | Julie Rubinstein President and COO | SOpen-market sale Common Stock10b5-1 | -5,800 | $28.56 | $166k | 377,802 | 7 d ago |
| Oct 1, 2026 | Francis Lo Chief People Officer | MOption exercise Common Stock10b5-1 | +9,377 | $8.12 | $76k | 247,659 | 7 d ago |
| Oct 2, 2026 | Julie Rubinstein President and COO | MOption exercise Common Stock10b5-1 | +11,881 | $12.14 | $144k | 389,683 | 7 d ago |
| Oct 1, 2026 | Francis Lo Chief People Officer | SOpen-market sale Common Stock10b5-1 | -8,094 | $27.52 | $223k | 239,565 | 7 d ago |
| Oct 2, 2026 | Julie Rubinstein President and COO | SOpen-market sale Common Stock10b5-1 | -11,881 | $28.13 | $334k | 377,802 | 7 d ago |
| Oct 1, 2026 | Francis Lo Chief People Officer | SOpen-market sale Common Stock10b5-1 | -18,698 | $28.61 | $535k | 220,867 | 7 d ago |
| Oct 5, 2026 | Julie Rubinstein President and COO | MOption exercise Common Stock10b5-1 | +11,881 | $12.14 | $144k | 389,683 | 7 d ago |
| Oct 1, 2026 | Francis Lo Chief People Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -8,038 | $0.00 | $0 | 16,075 | 7 d ago |
| Oct 5, 2026 | Julie Rubinstein President and COO | SOpen-market sale Common Stock10b5-1 | -6,699 | $28.82 | $193k | 382,984 | 7 d ago |
| Oct 5, 2026 | Julie Rubinstein President and COO | SOpen-market sale Common Stock10b5-1 | -5,182 | $29.67 | $154k | 377,802 | 7 d ago |
| Oct 1, 2026 | Francis Lo Chief People Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -9,377 | $0.00 | $0 | 56,259 | 7 d ago |
| Oct 1, 2026 | Julie Rubinstein President and COO | MOption exercise Stock Option (right to buy)derivative10b5-1 | -11,881 | $0.00 | $0 | 367,896 | 7 d ago |
| Oct 1, 2026 | Francis Lo Chief People Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -9,377 | $0.00 | $0 | 93,765 | 7 d ago |
| Oct 2, 2026 | Julie Rubinstein President and COO | MOption exercise Stock Option (right to buy)derivative10b5-1 | -11,881 | $0.00 | $0 | 356,015 | 7 d ago |
| Oct 5, 2026 | Julie Rubinstein President and COO | MOption exercise Stock Option (right to buy)derivative10b5-1 | -11,881 | $0.00 | $0 | 344,134 | 7 d ago |
| Sep 16, 2026 | Francis Lo Chief People Officer | MOption exercise Common Stock10b5-1 | +53,091 | $12.14 | $645k | 283,804 | 24 d ago |
| Sep 16, 2026 | Francis Lo Chief People Officer | MOption exercise Common Stock10b5-1 | +13,398 | $8.46 | $113k | 297,202 | 24 d ago |
| Sep 16, 2026 | Francis Lo Chief People Officer | MOption exercise Common Stock10b5-1 | +15,629 | $3.99 | $62k | 312,831 | 24 d ago |
| Sep 16, 2026 | Francis Lo Chief People Officer | MOption exercise Common Stock10b5-1 | +23,442 | $8.12 | $190k | 336,273 | 24 d ago |
| Sep 16, 2026 | Francis Lo Chief People Officer | SOpen-market sale Common Stock10b5-1 | -107,537 | $28.02 | $3.0M | 228,736 | 24 d ago |
| Sep 16, 2026 | Francis Lo Chief People Officer | SOpen-market sale Common Stock10b5-1 | -7,869 | $28.57 | $225k | 220,867 | 24 d ago |
| Sep 16, 2026 | Francis Lo Chief People Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -53,091 | $0.00 | $0 | 79,155 | 24 d ago |
| Sep 16, 2026 | Francis Lo Chief People Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -13,398 | $0.00 | $0 | 24,113 | 24 d ago |
| Sep 16, 2026 | Francis Lo Chief People Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -15,629 | $0.00 | $0 | 65,636 | 24 d ago |
| Sep 16, 2026 | Francis Lo Chief People Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -23,442 | $0.00 | $0 | 103,142 | 24 d ago |
| Sep 15, 2026 | Susan Bobulsky Chief Commercial Officer, MRD | SOpen-market sale Common Stock10b5-1 | -1,195 | $27.00 | $32k | 395,794 | 25 d ago |
| Aug 31, 2026 | Katey Einterz Owen director | GGift Common Stock | -12,539 | - | - | 66,100 | 40 d ago |
| May 15, 2025 | Kyle Piskel Chief Financial Officer | AGrant or award Common Stock | +7,815 | $0.00 | $0 | 279,325 | May 19, 2025 |
| May 16, 2025 | Kyle Piskel Chief Financial Officer | SOpen-market sale Common Stock | -1,929 | $8.89 | $17k | 277,396 | May 19, 2025 |
| May 1, 2025 | Harlan S Robins Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +68,412 | $6.32 | $432k | 1,347,936 | May 5, 2025 |
| May 1, 2025 | Harlan S Robins Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -68,412 | $7.35 | $503k | 1,279,524 | May 5, 2025 |
| May 1, 2025 | Harlan S Robins Chief Scientific Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -68,412 | $0.00 | $0 | 0 | May 5, 2025 |
| Mar 24, 2025 | Harlan S Robins Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +1,698 | $6.32 | $11k | 1,281,222 | Mar 26, 2025 |
| Mar 24, 2025 | Harlan S Robins Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -1,698 | $9.00 | $15k | 1,279,524 | Mar 26, 2025 |
| Mar 24, 2025 | Harlan S Robins Chief Scientific Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,698 | $0.00 | $0 | 68,412 | Mar 26, 2025 |
| Mar 14, 2025 | Kyle Piskel Chief Financial Officer | MOption exercise Common Stock | +2,500 | $6.32 | $16k | 271,510 | Mar 17, 2025 |
| Mar 13, 2025 | Michelle Renee Griffin director | SOpen-market sale Common Stock | -36,291 | $7.19 | $261k | 15,394 | Mar 17, 2025 |
| Mar 14, 2025 | Kyle Piskel Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative | -2,500 | $0.00 | $0 | 0 | Mar 17, 2025 |
| Mar 12, 2025 | Robert Hershberg director | SOpen-market sale Common Stock | -53,000 | $7.59 | $402k | 69,690 | Mar 12, 2025 |
| Mar 10, 2025 | Peter M Neupert director | MOption exercise Common Stock | +50,000 | $4.07 | $204k | 234,690 | Mar 12, 2025 |
| Mar 10, 2025 | Peter M Neupert director | SOpen-market sale Common Stock | -10,000 | $7.05 | $71k | 224,690 | Mar 12, 2025 |
| Mar 10, 2025 | Peter M Neupert director | MOption exercise Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | Mar 12, 2025 |
| Mar 4, 2025 | Harlan S Robins Chief Scientific Officer | AGrant or award Common Stock | +355,000 | $0.00 | $0 | 1,376,180 | Mar 6, 2025 |
| Mar 4, 2025 | Michelle Renee Griffin director | AGrant or award Common Stock10b5-1 | +15,394 | $0.00 | $0 | 67,349 | Mar 6, 2025 |
| Mar 4, 2025 | Robert Hershberg director | AGrant or award Common Stock | +15,394 | $0.00 | $0 | 122,690 | Mar 6, 2025 |
| Mar 4, 2025 | Peter M Neupert director | AGrant or award Common Stock | +15,394 | $0.00 | $0 | 184,690 | Mar 6, 2025 |
| Mar 4, 2025 | Katey Einterz Owen director | AGrant or award Common Stock | +15,394 | $0.00 | $0 | 72,629 | Mar 6, 2025 |
| Mar 4, 2025 | Michael J Pellini director | AGrant or award Common Stock | +15,394 | $0.00 | $0 | 69,690 | Mar 6, 2025 |
| Mar 4, 2025 | Chad M Robins CEO and Chairman | AGrant or award Common Stock | +355,000 | $0.00 | $0 | 2,931,701 | Mar 6, 2025 |
| Mar 4, 2025 | Julie Rubinstein President and COO | AGrant or award Common Stock | +175,000 | $0.00 | $0 | 647,754 | Mar 6, 2025 |
| Mar 4, 2025 | Kyle Piskel Chief Financial Officer | AGrant or award Common Stock | +125,000 | $0.00 | $0 | 279,330 | Mar 6, 2025 |
| Mar 4, 2025 | Sharon Benzeno Chief Commercial Ofc Imm Med | AGrant or award Common Stock | +109,973 | $0.00 | $0 | 437,388 | Mar 6, 2025 |
| Mar 4, 2025 | Susan Bobulsky Chief Commercial Officer, MRD | AGrant or award Common Stock | +119,971 | $0.00 | $0 | 373,261 | Mar 6, 2025 |
| Mar 4, 2025 | Francis Lo Chief People Officer | AGrant or award Common Stock | +99,976 | $0.00 | $0 | 353,721 | Mar 6, 2025 |
| Mar 5, 2025 | Harlan S Robins Chief Scientific Officer | SOpen-market sale Common Stock | -40,603 | $6.98 | $283k | 1,335,577 | Mar 6, 2025 |
| Mar 5, 2025 | Julie Rubinstein President and COO | SOpen-market sale Common Stock | -40,044 | $6.98 | $280k | 607,710 | Mar 6, 2025 |
| Mar 5, 2025 | Kyle Piskel Chief Financial Officer | SOpen-market sale Common Stock | -3,103 | $6.97 | $22k | 276,227 | Mar 6, 2025 |
| Mar 5, 2025 | Sharon Benzeno Chief Commercial Ofc Imm Med | SOpen-market sale Common Stock | -41,600 | $6.98 | $290k | 395,788 | Mar 6, 2025 |
| Mar 5, 2025 | Susan Bobulsky Chief Commercial Officer, MRD | SOpen-market sale Common Stock | -26,023 | $6.98 | $182k | 347,238 | Mar 6, 2025 |
| Mar 5, 2025 | Francis Lo Chief People Officer | SOpen-market sale Common Stock | -7,085 | $6.98 | $49k | 346,636 | Mar 6, 2025 |
| Mar 4, 2025 | Robert Hershberg director | AGrant or award Stock Option (right to buy)derivative | +23,726 | $0.00 | $0 | 23,726 | Mar 6, 2025 |
| Mar 4, 2025 | Peter M Neupert director | AGrant or award Stock Option (right to buy)derivative | +23,726 | $0.00 | $0 | 23,726 | Mar 6, 2025 |
| Mar 4, 2025 | Katey Einterz Owen director | AGrant or award Stock Option (right to buy)derivative | +23,726 | $0.00 | $0 | 23,726 | Mar 6, 2025 |
| Mar 4, 2025 | Michael J Pellini director | AGrant or award Stock Option (right to buy)derivative | +23,726 | $0.00 | $0 | 23,726 | Mar 6, 2025 |
| Mar 6, 2025 | Michelle Renee Griffin director | SOpen-market sale Common Stock10b5-1 | -15,664 | $7.94 | $124k | 51,685 | Mar 6, 2025 |
| Mar 5, 2025 | Chad M Robins CEO and Chairman | SOpen-market sale Common Stock | -81,206 | $6.98 | $567k | 2,850,495 | Mar 6, 2025 |
| Mar 5, 2025 | Harlan S Robins Chief Scientific Officer | SOpen-market sale Common Stock | -56,053 | $6.99 | $392k | 1,279,524 | Mar 6, 2025 |
| Mar 5, 2025 | Julie Rubinstein President and COO | SOpen-market sale Common Stock | -19,461 | $6.99 | $136k | 588,249 | Mar 6, 2025 |
| Mar 5, 2025 | Kyle Piskel Chief Financial Officer | SOpen-market sale Common Stock | -253 | $6.98 | $1,766 | 275,974 | Mar 6, 2025 |
| Mar 5, 2025 | Sharon Benzeno Chief Commercial Ofc Imm Med | SOpen-market sale Common Stock | -3,065 | $6.99 | $21k | 392,723 | Mar 6, 2025 |
| Mar 5, 2025 | Francis Lo Chief People Officer | SOpen-market sale Common Stock | -13,790 | $6.99 | $96k | 332,846 | Mar 6, 2025 |
| Mar 4, 2025 | Michelle Renee Griffin director | AGrant or award Stock Option (right to buy)derivative10b5-1 | +23,726 | $0.00 | $0 | 23,726 | Mar 6, 2025 |
| Mar 4, 2025 | Susan Bobulsky Chief Commercial Officer, MRD | AGrant or award Stock Option (right to buy)derivative | +180,029 | $0.00 | $0 | 180,029 | Mar 6, 2025 |
| Mar 5, 2025 | Chad M Robins CEO and Chairman | SOpen-market sale Common Stock | -36,145 | $6.99 | $253k | 2,814,350 | Mar 6, 2025 |
| Mar 5, 2025 | Chad M Robins CEO and Chairman | AGrant or award Common Stock | +247,117 | $0.00 | $0 | 3,061,467 | Mar 6, 2025 |
| Mar 5, 2025 | Kyle Piskel Chief Financial Officer | SOpen-market sale Common Stock | -6,964 | $6.99 | $49k | 269,010 | Mar 6, 2025 |
| Mar 4, 2025 | Sharon Benzeno Chief Commercial Ofc Imm Med | AGrant or award Stock Option (right to buy)derivative | +165,027 | $0.00 | $0 | 165,027 | Mar 6, 2025 |
| Mar 4, 2025 | Francis Lo Chief People Officer | AGrant or award Stock Option (right to buy)derivative | +150,024 | $0.00 | $0 | 150,024 | Mar 6, 2025 |
| Mar 6, 2025 | Chad M Robins CEO and Chairman | SOpen-market sale Common Stock | -102,218 | $7.64 | $781k | 2,959,249 | Mar 6, 2025 |
| Feb 19, 2025 | Chad M Robins CEO and Chairman | MOption exercise Common Stock10b5-1 | +186,080 | $6.32 | $1.2M | 2,762,781 | Feb 21, 2025 |
| Feb 19, 2025 | Chad M Robins CEO and Chairman | SOpen-market sale Common Stock10b5-1 | -186,080 | $8.46 | $1.6M | 2,576,701 | Feb 21, 2025 |
| Feb 20, 2025 | Chad M Robins CEO and Chairman | MOption exercise Common Stock10b5-1 | +99,107 | $6.32 | $626k | 2,675,808 | Feb 21, 2025 |
| Feb 20, 2025 | Chad M Robins CEO and Chairman | SOpen-market sale Common Stock10b5-1 | -99,107 | $8.44 | $836k | 2,576,701 | Feb 21, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Sharon BenzenoChief Commercial Ofc Imm Med
- Susan BobulskyChief Commercial Officer, MRD
- Michelle Renee Griffindirector
- Robert Hershbergdirector, officer
- Francis LoChief People Officer
- Peter M Neupertdirector
- Katey Einterz Owendirector
- Kyle PiskelChief Financial Officer
- Michael J Pellinidirector
- Chad M RobinsCEO and Chairman
- Harlan S RobinsChief Scientific Officer
- Julie RubinsteinPresident and COO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.